NightBalance acquired by Royal Philips - Gilde Healthcare

NightBalance acquired by Royal Philips

7 mei 2018

Utrecht, The Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has acquired NightBalance, a portfolio company from specialist investor Gilde Healthcare. Netherlands-based NightBalance is a digital health scale-up company commercializing an innovative, easy to use device to treat positional obstructive sleep apnea and positional snoring. With the acquisition of NightBalance, Philips expands its Sleep & Respiratory Care portfolio. Financial details of the transaction were not disclosed.

NightBalance’s Sleep Position Trainer (SPT) was designed as a patient friendly treatment alternative for people who suffer from positional obstructive sleep apnea. The SPT gently prompts them not to sleep on their back, avoiding the apneas from occurring during sleep. The SPT is CE-marked and is currently marketed in select countries in Europe. The acquisition will help Philips to further expand its leadership position in the growing home care market, and its ability to deliver integrated solutions that drive efficiencies and improved outcomes. Philips already offers a broad range of care solutions for people living with obstructive sleep apnea.

 

About Gilde Healthcare

Gilde Healthcare is a specialized European healthcare investor managing €1 billion across two business lines: a venture & growth capital fund and a lower mid-market buy-out fund. Gilde Healthcare’s venture & growth capital fund invests in digital health, medtech and therapeutics. The portfolio companies are based in Europe and North America. Gilde Healthcare’s lower mid-market buy-out fund invests in profitable European healthcare services companies with a focus on the Benelux and DACH-region. The portfolio consists of healthcare providers, suppliers of medical products and other service providers in the healthcare market.
For more information, visit the company’s website at www.gildehealthcare.com

Gilde Healthcare company Tagworks Pharmaceuticals Announces Initiation of Third Dose Level in Ongoing Phase 1 Clinical Trial of TGW101 for the Treatment of Solid Tumors

TGW101 is a next-generation, first-in-class ADC targeting TAG-72 with an MMAE payload, developed based on Tagworks proprietary Click-to-Release linker chemistry; TGW101 is the first bioorthogonal, in vivo click chemistry-activated ADC, which enables superior control of tumor...
10 september 2025

Gilde Healthcare appoints Dr. Christian Stark as Group CEO of its globally operating medical technology group

The medical technology group, which includes two manufacturers of surgical instruments in the Tuttlingen region, Koscher & Würtz and Christian Diener, has appointed Dr. Christian Stark as Chief Executive Officer (CEO) with effect from September...
3 september 2025

Gilde Healthcare kondigt succesvolle exit aan van portfoliobedrijf Novicare, een specialistische behandeldienst met medische en paramedische (tele)zorg, aan Gimv

Gilde Healthcare, de gespecialiseerde investeerder in de zorgsector, heeft een overeenkomst bereikt over de verkoop van haar Nederlandse portfoliobedrijf Novicare aan Gimv*. Novicare biedt uitbestede medische en paramedische (tele)zorg. Het bedrijf is gespecialiseerd in ouderenzorg...
28 augustus 2025